<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04630522</url>
  </required_header>
  <id_info>
    <org_study_id>JMT103CN01-1</org_study_id>
    <nct_id>NCT04630522</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of JMT103 in Patients With Bone Metastases From Solid Tumors</brief_title>
  <official_title>A Randomized, Open-Label, Dose-finding, Multi-centre, Phase Ib Study toEvaluate the Efficacy and Safety of JMT103 in Patients With Bone Metastases From Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai JMT-Bio Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai JMT-Bio Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open-label, dose-finding, multi-centre, phase Ⅰb study to evaluate the&#xD;
      efficacy and safety of JMT103 in patients with bone metastases from solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this trial is to evaluate the efficacy and safety of JMT103 in patients with&#xD;
      bone metastases from solid tumors.&#xD;
&#xD;
      Eligible patients will be randomly assigned to receive JMT103 120mg subcutaneously (SC) every&#xD;
      4 weeks (Q4W), 120mg subcutaneously (SC) every 8 weeks (Q8W) and 180mg subcutaneously (SC)&#xD;
      every 8 weeks (Q8W) in a 1:1:1 ratio. Patients will receive the treatment until the&#xD;
      completion of 48 weeks of treatment, intolerable toxicity, loss to follow-up, withdrawal&#xD;
      (patient's decision or investigator's decision), whichever comes first.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 31, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change of urinary N-terminal telopeptide of type 1 collagen/creatine (U-NTX/Cr) from baseline to week 13</measure>
    <time_frame>From enrollment to week 13.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and type of adverse events (AEs)</measure>
    <time_frame>From enrollment to 90 days after the last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Skeletal-related event（SRE）</measure>
    <time_frame>From enrollment to 90 days after the last dose</time_frame>
    <description>SRE is defined as pathological fracture, radiotherapy to bone, surgery to bone, or spinal cord compression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pain Score (Brief Pain Inventory-Short Form，BPI-SF)</measure>
    <time_frame>From enrollment to 90 days after the last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough plasma concentration （Ctrough）</measure>
    <time_frame>From enrollment to 90 days after the last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in serum C-terminus peptide (of Type 1 Collagen) from baseline</measure>
    <time_frame>From enrollment to 90 days after the last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in serum bone-specific alkaline phosphatase (bALP) from baseline</measure>
    <time_frame>From enrollment to 90 days after the last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with anti-JMT103 antibodies</measure>
    <time_frame>From enrollment to 90 days after the last dose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Bone Metastases From Solid Tumors</condition>
  <arm_group>
    <arm_group_label>JMT103- 120 mg SC Q4W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients will receive JMT103 120 mg SC Q4W for up to 13 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JMT103- 120 mg SC Q8W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients will receive JMT103 120 mg SC Q8W for up to 7 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JMT103- 180 mg SC Q8W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients will receive JMT103 180 mg SC Q8W for up to 7 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug: JMT103- 120 mg SC Q4W</intervention_name>
    <description>JMT103 is administered subcutaneously at a dose of 120 mg on day 1 of each 4-week cycle.</description>
    <arm_group_label>JMT103- 120 mg SC Q4W</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug: JMT103- 120 mg SC Q8W</intervention_name>
    <description>JMT103 is administered subcutaneously at a dose of 120 mg on day 1 of each 8-week cycle.</description>
    <arm_group_label>JMT103- 120 mg SC Q8W</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug: JMT103- 180 mg SC Q8W</intervention_name>
    <description>JMT103 is administered subcutaneously at a dose of 180 mg on day 1 of each 8-week cycle.</description>
    <arm_group_label>JMT103- 180 mg SC Q8W</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dietary Supplement: Calcium Dietary Supplement: Vitamin D</intervention_name>
    <description>Calcium is given orally at a dose of 500 mg at least, once daily. Vitamin D is given orally at a dose of 400 IU at least, once daily.</description>
    <arm_group_label>JMT103- 120 mg SC Q4W</arm_group_label>
    <arm_group_label>JMT103- 120 mg SC Q8W</arm_group_label>
    <arm_group_label>JMT103- 180 mg SC Q8W</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Fully informed and signed informed consent.&#xD;
&#xD;
          2. Male or female, 18 years and older.&#xD;
&#xD;
          3. Histologically/cytologically confirmed malignant solid tumors.&#xD;
&#xD;
          4. Radiographic evidence of at least one bone metastasis.&#xD;
&#xD;
          5. Eligible fertile patients (male and female) must agree to use an effective method of&#xD;
             contraception with their partners from the signing of informed consent until at least&#xD;
             6 months after the last treatment.&#xD;
&#xD;
          6. Adequate organ functions.&#xD;
&#xD;
          7. Albumin-corrected serum calcium ≥ 1 x lower limit of normal (LLN) at screening&#xD;
             (calcium supplement is not allowed within 8 hours prior to screening).&#xD;
&#xD;
          8. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.&#xD;
&#xD;
          9. Life expectancy ≥ 6 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous or present osteomyelitis or osteonecrosis of the jaw; unhealed dental or oral&#xD;
             surgery wounds; acute disease of the tooth or jaw requiring oral surgery; and invasive&#xD;
             dental surgery planned to be received during the study;&#xD;
&#xD;
          2. Radiotherapy or orthopaedic surgery is planned for patients during the study;&#xD;
&#xD;
          3. Known symptomatic brain metastases.&#xD;
&#xD;
          4. Abnormal bone metabolism (such as Paget's disease, Cushing's syndrome,&#xD;
             hyperprolactinemia), rheumatoid arthritis, parathyroid disease&#xD;
&#xD;
          5. Clinically significant disease (such as uncontrolled diabetes, congestive heart&#xD;
             failure, hypertension&gt;150/90 mmHg).&#xD;
&#xD;
          6. Known hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus&#xD;
             (HIV) or other active viral infection.&#xD;
&#xD;
          7. Systemic therapy of active bacterial infection or fungal infection within 7 days prior&#xD;
             to randomization.&#xD;
&#xD;
          8. Pregnant or lactating women.&#xD;
&#xD;
          9. Prior use of antibody against nuclear factor kappa-B (NFκB) ligand (RANKL).&#xD;
&#xD;
         10. Participated in other clinical studies and received other experimental drugs within 4&#xD;
             weeks prior to randomization.&#xD;
&#xD;
         11. Prior use of bisphosphonate within 4 weeks prior to randomization.&#xD;
&#xD;
         12. Prior use of one of following osteoporosis medications within 6 months prior to&#xD;
             randomization (Parathyroid hormone (PTH) analogue, calcitonin, osteoprotegerin,&#xD;
             mithramycin, and strontium).&#xD;
&#xD;
         13. Adverse reactions from the previous anti-tumor treatment have not yet recovered to ≤&#xD;
             level 1 based on CTCAE 5.0 (except for the toxicity without safety risk judged by the&#xD;
             investigator, such as hair loss)&#xD;
&#xD;
         14. Known hypersensitivity to any of the products to be administered during the study&#xD;
             (such as JMT103)&#xD;
&#xD;
         15. Not suitable for this study as determined by the investigator due to other reasons.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin Li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai East Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jin Li, MD</last_name>
    <phone>86-21-38804518</phone>
    <email>lijin@csco.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Huiping Li, MD</last_name>
    <phone>86-10-88196827</phone>
    <email>huipingli2012@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai East Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200123</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Li, MD</last_name>
      <phone>86-21-38804518</phone>
      <email>lijin@csco.org.cn</email>
    </contact>
    <investigator>
      <last_name>Jin Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 2, 2020</study_first_submitted>
  <study_first_submitted_qc>November 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2020</study_first_posted>
  <last_update_submitted>November 9, 2020</last_update_submitted>
  <last_update_submitted_qc>November 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Bone Neoplasms</mesh_term>
    <mesh_term>Bone Marrow Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

